RxDoctor Payments Data

Charlie Gnaim, MD

Interventional Cardiology · Humble, TXNPI 1245386424

Payments from drug & device makers

$43,996in general payments, 2019–2025

Across 451 payments — averaging $97.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$33K
  • Abbott$2K
  • Boston Scientific$1K
  • Novartis$1K
  • Bard Peripheral Vascular, Inc.$835
  • Johnson & Johnson$509
  • plus $5K from 40 others

What the payments were for

  • Royalty or licence$30,75870%
  • Food & beverage$13,15830%
  • Education$800%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,996 in reported general payments places this provider in the 80th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$263,732
Medicare patients
622
Services billed
1,985

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban196$194,669
EntrestoSacubitril/Valsartan83$78,768
XareltoRivaroxaban73$67,467
Repatha SureclickEvolocumab59$53,754
Praluent PenAlirocumab16$12,694
Repatha SyringeEvolocumab14$12,151
BrilintaTicagrelor15$10,421
Valsartan314$7,555
Nebivolol Hcl89$6,542
Rosuvastatin Calcium291$4,844
Metoprolol Succinate223$3,095
Bumetanide75$2,799
Nifedipine ErNifedipine66$2,184
Potassium Chloride117$2,118
Ezetimibe68$1,791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$199$194,669196 claims
NovartisEntresto$1,226$78,76883 claims
Johnson & JohnsonXarelto$509$67,46773 claims
AstraZenecaBrilinta$28$10,42115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Humble

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →